Arvinas CFO and CEO Sell Thousands of Shares in Routine RSU Tax Sale, Stock Holds Steady Momentum

Insider Activity Highlights a Routine Tax‑Related Sale

Arvinas Inc. has just reported a sale of 1,108 shares by Chief Accounting Officer David Loomis on February 23, 2026. The transaction, driven by the automatic sale of a portion of the CO’s restricted‑stock‑unit (RSU) vesting to cover tax withholding, closed at $12.16 per share—slightly below the closing price of $12.37. Because the sale was mandatory and not discretionary, it does not signal a loss of confidence in the company’s prospects. Instead, it reflects the routine exercise of RSU settlement rules that many public companies follow.

Current Insider Trading in Context

In the week ending February 23, Arvinas’ senior executives—including CEO Randy Teel, CFO Andrew Saik, and others—made a handful of sales, each clearing roughly 4,000 to 5,700 shares at the same $11.89 price. These moves, along with Loomis’s tax‑sale, suggest a broader pattern of short‑term liquidity management rather than a strategic divestment. The overall insider‑ownership profile remains high; after the February 23 sale, Loomis still owns 29,692 shares, or about 3.3% of the outstanding shares, a level that is comfortably above the 5% threshold for routine trading disclosures.

Implications for Investors

The fact that the sale was automatically triggered by RSU vesting means it is largely mechanical and does not provide a signal about the company’s operational health. The share price, which has been up 12.5% over the last week and 0.08% over the month, remains well below the 52‑week high of $18.93, suggesting there is still room for upside. For investors, the key takeaway is that insider activity at this level is typical for a growing biotech with a complex compensation structure. Unless future sales are accompanied by negative disclosures or a change in the company’s strategic direction, the trades are unlikely to influence short‑term valuation.

David Loomis: A Profile of Consistency

Loomis’s insider‑trading history over the past 18 months shows a mix of buys and sells. The largest buy was 11,825 shares on May 9, 2025, followed by a 1,016‑share sale on February 13, 2026. His transactions have generally occurred near the market price, with most sales priced close to the day’s close. This pattern indicates that Loomis typically follows the company’s vesting schedules and standard exercise procedures, rather than timing trades to exploit price movements. His consistent holding of roughly 30,000 shares—well above the 5% reporting threshold—demonstrates confidence in the company’s long‑term prospects, even as the company navigates the challenges of a clinical‑stage biotech.

Looking Ahead

Arvinas is positioned in a rapidly expanding protein‑degradation market, with projected CAGR over 30 % through 2033. The company’s upcoming investor conferences and the upcoming Q4 earnings release will be the real bellwethers for valuation. While insider trades provide useful context, the current transactions—particularly the tax‑sale—are routine and should not be read as a red flag. For investors, the focus should remain on the company’s clinical pipeline, partnership announcements, and the broader market’s appetite for PROTACs and related therapeutics.